Poll results: Medical education falters on pain relief

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain.

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain. Of those who responded to ONI’s June poll question-“Do you feel your medical school education in pain relief and opioid pharmacology was adequate?”-71% answered in the negative. Only 14% said that their pain management training was adequate, while 16% said they weren’t sure.

Although the International Association for the Study of Pain has established guidelines for pain management, compliance is spotty, said Kathleen M. Foley, MD, of Memorial Sloan-Kettering Cancer Center, in New York.

The poll was linked to the article, “US cancer patients still plagued by undertreated pain” (June 2008, page 20). To respond to this month’s poll (on page 2), visit www.CancerNetwork.com.

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Related Content